Prostate specific antigen utilization trends in an academic hospital in Argentina.
DOI:
https://doi.org/10.31053/1853.0605.v76.n4.25185Keywords:
prostatic neoplasms, mass screening, prostate-specific antigen, medical overuseAbstract
Background. Although prostate cancer (PC) screening with prostate-specific antigen (PSA) determination could decrease mortality, concerns about the potential risk of overdiagnosis led to recommendations against this preventive practice. The objective of this study was to describe the trend in PSA determinations in men between 40 and 79 years old, affiliated to a Health Maintenance Organization (HMO) of an academic hospital in the city of Buenos Aires, Argentina, and its association with the recommendations stated by the U.S. Preventive Task Force (USPSTF) and the Instituto Nacional del Cáncer in Argentina.
Methods. We analyzed a time series of aggregated data. We calculated the annual age-standardized rates of accumulated determinations of PSA for every 100 affiliates without a personal history of PC. Additionally, we compared trends by age groups every 10 years. We used Joinpoint and MS Excel programs.
Results. Between 2006 and 2011 there was a growing trend in the number of PSA determinations, with an annual average of + 1.2% (95% CI, -1.0 to +3.5). Between 2011 and 2015, the number of determinations began to decrease, with a percentage annual average of -4.1% (-6.9 to -1.1).
Conclusion. We found a gradual decrease in PSA utilization in men between 40 and 79 years old after the 2012 USPSTF recommendation against prostate cancer screening.
Downloads
References
Ferlay J, Soerjomataram I, Ervik M et al.GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Disponible en: http://globocan.iarc.fr
Ballesteros I, Limardo L, Abriata G. Vigilancia epidemiológica del cáncer, análisis de situación de salud por cáncer. Argentina, 2016; 18–43. Available from: http://www.msal.gob.ar/images/stories/bes/graficos/0000000925cnt-2016-12-21-boletin-epidemiologia.pdf, ingreso el 05/06/2019
Tice JA. Prostate specific antigen to screen for prostate cancer. Calif Technol Assess Forum. 2012;1–57
Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013 Jan 31;(1)
Moynihan R, Doust J, Henry D. Preventing overdiagnosis: how to stop harming the healthy. BMJ. 2012; 344:e3502
Calonge N, Petitti DB , DeWitt TG et al. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008, 149 (3):185-91
Li J, Berkowitz Z, Richards TB, Richardson LC. Shared decision making in prostate-specific antigen testing with men older than 70 years. J Am Board Fam Med. 2013 Jul-Aug; 26(4): 401–408
Prasad SM, Drazer MW, Huo D, et al. 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA. 2012 Apr 25;307(16):1692–4
Moyer VA, LeFevre ML , Siu AL et al. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012 Jul 17;157(2):120–34
Grossman DC et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018 May 8;319(18):1901-1913
Rastreo de cáncer de próstata. Instituto Nacional del Cáncer, Ministerio de Salud y Desarrollo Social de la Nación. Argentina. Disponible en:
https://www.argentina.gob.ar/salud/cancer/tipos/cancer-de-prostata, ingreso el 15/07/2019
Fleshner, K., Carlsson, S. V., & Roobol, M. J. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nature Reviews Urology. 2017 Jan; 14(1), 26–37.
Zargar, H., van den Bergh, R., Moon, D., Lawrentschuk, N., Costello, A., & Murphy, D. The Impact Of United States Preventive Services Task Force (USPSTF) Recommendations Against PSA Testing On PSA Testing In Australia. BJU International. 2017 Jan; 119(1):110-115.
Zakaria, A. S., Dragomir, A., Brimo, F., Kassouf, W., Tanguay, S., & Aprikian, A. Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening. BMC Urology. 2018; 18(1):69
Published
How to Cite
Issue
Section
License
The Faculty of Medical Sciences Journal (RFCM) subscribes to the Open Access policy and does not charge authors fees for publishing, nor does it charge readers fees for accessing published articles (APC).
